Savannah State University welcomes Make-A-Wish family
Mason Downey was diagnosed with cystic fibrosis at age five, a genetic disorder that primarily affects the lungs and digestive system. His family traveled from Indiana to Savannah to allow Mason the chance to realize a dream.
'I have been using microscopes to explore plankton and other stuff,' Downey said. 'And then I've also been exploring how to identify a dolphin by their sounds.'
Thanks to Make-a-Wish, Downey is getting the chance to learn alongside marine biology students. It is a passion fueled by his desire to protect ocean life.
'I really just want to help the ocean because it's slowly dying, and I just really feel bad for it,' he said.
Savannah State University's marine biology department stepped in to help Downey learn more about the life of an ocean scientist. They set up several labs for the 12-year-old to observe, each focusing on a different aspect of marine biology.
'We're so delighted to just be part of his journey,' Victoria Young said.
The experience has touched not only Downey, but his family as well. His mother, Kristen Downey, left with a full heart.
'Being here at Savannah State [University] is really nice because it's exciting to see him living this dream,' Kristen said.
'Learning about becoming a marine biologist, learning about college in general, so that in a few years he can go to college and this maybe one of his choices. I'm just very excited as a mom to see him get to experience this.'
With hands-on practice under his belt, Downey is moving full steam ahead with plans for his future.
'I really want to move down to a coastline and become a marine biologist,' said Mason.
Make-A-Wish Georgia grants life-changing wishes for children with critical illnesses.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CORAL SPRINGS, FL / / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the "Microcapsule Age." To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH "The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics." noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the "King of Anti-Aging Molecules," plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables "zero release in the stomach and sustained release in the intestine." Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments "We are not just creating better products-we are building a platform for the future of longevity," said Dr. Juliane Hitzel, CEO of CELFULL. "With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science." From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact:maggie@ | Email: maggie@ SOURCE: CELFULL View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Washington Post
an hour ago
- Washington Post
Asking Eric: After ugly comments, brother invites himself to party
Dear Eric: Nearly eight months ago, my 81-year-old brother lashed out saying hateful and hurtful things about our youngest sister. At the time, I suspected he was drunk and probably frustrated from the repeated episodes of our sister's illnesses and problems, some of which have been caused by her own serious eating disorder, depression and occasional binge drinking.
Yahoo
an hour ago
- Yahoo
Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks
With persistent macro uncertainty and shifting market trends, healthcare remains one of the most defensive and fundamentally sound sectors for investors. The US healthcare industry continues to deliver both stability and long-term growth potential. In the latter half of 2025, these three healthcare stocks emerge as top picks for their compelling mix of innovation and favourable industry trends. Johnson & Johnson (J&J) is a global healthcare company with its core businesses in innovative medicine and MedTech. In the first quarter of 2025 (1Q 2025), J&J reported 2.4% year-on-year (YoY) increase in revenue, bringing in US$21.9 billion. This growth can be attributed to a strong revenue growth of 4.2% YoY in innovative medicine. A key driver for the rise is the 20.4% YoY in revenue growth in the oncology segment. This increase is due to medicine such as DARZALEX and ERLEADA experiencing share gains amid market growth.J&J's MedTech division recorded a strong 4.1% YoY revenue growth. The cardiovascular segment led this jump in revenue with a 17% YoY revenue growth. This growth is due to strong global procedure volumes and successful new product launches. The firm's internal forecast for sales of its key products by 2027/2028 is also higher than current market estimates. For instance, its pipeline product, the intravesical drug releasing system, is forecasted to have three times the product sales compared to current market estimates by 2027/ presents an opportunity for investors to capitalise on the potential upside which is not yet priced into the stock. This upside will be driven by J&J's internal forecasts, which signal confidence in its operations. Thermo Fisher is a top name in biopharmaceutical research, particularly in drug discovery and 1Q 2025, Thermo Fisher reported revenue of US$10.36 billion, along with organic revenue growth of 1% YoY. The firm's net profits climbed 13.5% YoY to US$1.5 billion in 1Q 2025. This strong growth was supported by the increased operational efficiencies with the partnership with the Chan Zuckerberg Institute for Advanced Biological partnership pioneers new technologies for improved human cell visualisation, providing scientists with better data insights and accelerating research cycles. In February 2025, Thermo Fisher also announced a US$4.1 billion acquisition of Solventum's Purification & Filtration Purification & Filtration business offerings enhance Thermo Fisher's current bioproduction services. This acquisition boosts Thermo Fisher's biologics production capabilities, thereby improving productivity. This deal also opens opportunities to cross-sell filtration and purification solutions alongside existing bioprocessing offerings. These developments demonstrate an effective strategic fit and may result in service margin expansion. UnitedHealth Group runs two primary businesses – UnitedHealthcare for healthcare insurance plans and Optum for technology-based healthcare services. UnitedHealth Group reported a 9.8% YoY increase in revenue in 1Q 2025, reaching US$109.6 billion. The company's net margin also improved to 5.7% in the same quarter. The previous year's quarter saw a net loss margin of 1.4%. The better performance was attributed to a strong performance for both UnitedHealthcare and Optum. In 1Q 2025, UnitedHealthcare's revenue grew by 12.2% YoY to US$84.6 billion. This growth was driven by a rise of 700,000 in the number of self-funded commercial plans sold. Another factor was the increased participation in senior and community-based offerings with 545,000 new members. In the same period, Optum saw an increase in revenue of 4.6% YoY to US$63.9 billion. This rise is led by a growth of Optum Rx which had an increase of 13 million scripts from new clients and deepening of existing relationships compared to 2024. Optum Insight also introduced artificial intelligence claim processing tools which increase productivity by over 20%. Moving forward, Optum Health announced its continued expansion of value-based care to serve 650,000 new patients in 2025. As the healthcare landscape transforms, these three companies offer stand-out opportunities amid uncertain markets. With these companies' blend of innovation and strong fundamentals, they provide a defensive anchor along with room for growth. These three stocks are well-positioned to deliver meaningful returns. It's a good idea to consider adding this trio into your buy watchlist of growth stocks. Generative AI is reshaping the stock market, but not in the way most investors think. It's not just about which companies are using AI. It's about how they're using it to unlock new revenue, dominate their markets, and quietly reshape the business world. Our latest FREE report 'How GenAI is Reshaping the Stock Market' breaks the hype down, so you can invest with greater clarity and confidence. Click here to download your copy today. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Gabriel Lim does not own shares in any of the companies mentioned. The post Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks appeared first on The Smart Investor. Sign in to access your portfolio
